A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc.
Thomas Jefferson University
Columbia University
Theseus Pharmaceuticals
Kyowa Kirin Co., Ltd.
Institut Cancerologie de l'Ouest
National Institutes of Health Clinical Center (CC)
Repos Pharma
Generic Devices Consulting, Inc.